<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Psychopharmacol Bull</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychopharmacol Bull</journal-id>
<journal-title-group>
<journal-title>Psychopharmacology Bulletin</journal-title>
</journal-title-group>
<issn pub-type="ppub">0048-5764</issn>
<issn pub-type="epub">2472-2448</issn>
<publisher>
<publisher-name>MedWorks Media Global</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31308580</article-id>
<article-id pub-id-type="pmc">6598782</article-id>
<article-id pub-id-type="publisher-manuscript">PB-49-2-28</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Evidence Based Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Revisiting Lithium: Utility for Behavioral Stabilization in Adolescents and Adults with Autism Spectrum Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mintz</surname>
<given-names>Mark</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hollenberg</surname>
<given-names>Emma</given-names>
</name>
</contrib>
<aff>Mintz, MD, Hollenberg, The Center for Neurological and Neurodevelopmental Health (CNNH NeuroHealth).</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">To whom correspondence should be addressed: Mark Mintz, MD, Chief Medical Officer, CNNH NeuroHealth, 2050 Voorhees Town Center, Voorhees, NJ 08043. Phone: 855-852-8150; Fax: 855-266-6180; E-mail: <email xlink:href="mailto:mmintz@cnnh.org">mmintz@cnnh.org</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Conflict of Interest</bold>
</p>
<p id="P29">The Authors declare that there are no conflicts of interest for the subject matter of this manuscript.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>20</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>49</volume>
<issue>2</issue>
<fpage>28</fpage>
<lpage>40</lpage>
<permissions>
<copyright-statement>Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<abstract>
<sec id="S1">
<title>Objectives</title>
<p id="P1">To examine the efficacy of lithium as a mood stabilizer for patients with autism spectrum disorder (ASD).</p>
</sec>
<sec id="S2">
<title>Experimental Design</title>
<p id="P2">A retrospective chart review was performed that examined the use of both extended and immediate release lithium carbonate in patients with ASD that were treated at a single clinical center (CNNH NeuroHealth). Clinical Global Impression (CGI) scales were used to quantify baseline severity of ASD and mood symptoms as well as improvement after treatment with lithium carbonate.</p>
</sec>
<sec id="S3">
<title>Principle Observations</title>
<p id="P3">Our retrospective chart review found that 73.7% (n = 14) of patients with ASD and concomitant maladaptive behaviors experienced “improvement” (CGI-I rating ≤ 3) with the addition of lithium to their treatment regimen. Those with comorbid “ADHD” phenotype were most predictive of an efficacious response (p = 0.038, Odds Ratio 12.2).</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">Lithium carbonate is a viable, efficacious and well tolerated alternative to various neuroleptics and other psychotropic medications for use as a mood stabilizer for patients with ASD.</p>
</sec>
</abstract>
<kwd-group>
<kwd>autism</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>lithium</kwd>
<kwd>irritability</kwd>
<kwd>adhd</kwd>
<kwd>self-injury</kwd>
<kwd>aggression</kwd>
<kwd>obsessive compulsive disorder</kwd>
<kwd>bipolar</kwd>
<kwd>mood stabilization</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>